The advent of oncolytic virotherapy in oncology: The Rigvir® story. Eur J Pharmacol. 2018 Oct 15;837:117-126
Multimodality treatment of a colorectal cancer stage IV patient with FOLFOX-4, bevacizumab, Rigvir Oncolytic Virus, and surgery. Rep Gastroenterol. 2018 Aug 23;12(2):457-465
Melanoma unknown primary brain metastasis treatment with ECHO-7 oncolytic virus RIGVIR®: a case report. Eur J Pharmacol. 2018 Oct 15;837:117-126
Long term treatment with the oncolytic ECHO 7 virus RIGVIR® of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient‐three case reports. Front Oncol. 2018 Feb 26;8:43
Effect of the oncolytic ECHO-7 virus RIGVIR® on the viability of cell lines of human origin in vitro. APMIS. 2016 Oct;124(10):896-904
Adapted ECHO-7 virus RIGVIR® immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015 Oct;25(5):421-6
A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®. Am J Case Rep. 2019 Jan 12;20:48-52.